{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:59:16Z","timestamp":1760403556376,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ijantimicag.2020.105921","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T21:25:14Z","timestamp":1581629114000},"page":"105921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain"],"prefix":"10.1016","volume":"55","author":[{"given":"Matteo","family":"Bassetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3846-4620","authenticated-orcid":false,"given":"Alessandro","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catia","family":"Cilloniz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele Roberto","family":"Giacobbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Vena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanel","family":"Amaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Graziano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ijantimicag.2020.105921_bib0001","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3810\/pgm.2010.03.2130","article-title":"Burden of community-acquired pneumonia in North American adults","volume":"122","author":"File","year":"2010","journal-title":"Postgrad Med"},{"issue":"Suppl 2","key":"10.1016\/j.ijantimicag.2020.105921_bib0002","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.ijantimicag.2020.105921_bib0003","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.ijantimicag.2020.105921_bib0004","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1378\/chest.07-1456","article-title":"A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU","volume":"133","author":"Restrepo","year":"2008","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ijantimicag.2020.105921_bib0005","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00134-019-05519-y","article-title":"Challenges in severe community-acquired pneumonia: a point-of-view review","volume":"45","author":"Torres","year":"2019","journal-title":"Intensive Care Med"},{"issue":"4","key":"10.1016\/j.ijantimicag.2020.105921_bib0006","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ccm.2018.08.007","article-title":"New Antibiotics for Pneumonia","volume":"39","author":"Bassetti","year":"2018","journal-title":"Clin Chest Med"},{"issue":"6","key":"10.1016\/j.ijantimicag.2020.105921_bib0007","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/1753465808098694","article-title":"Novel targets in the management of pneumonia","volume":"2","author":"Diaz","year":"2008","journal-title":"Ther Adv Respir Dis"},{"issue":"12","key":"10.1016\/j.ijantimicag.2020.105921_bib0008","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/657313","article-title":"Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia","volume":"51","author":"File","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.105921_bib0009","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pupt.2014.05.003","article-title":"New antimicrobial approaches to gram positive respiratory infections","volume":"32","author":"Liapikou","year":"2015","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.ijantimicag.2020.105921_bib0010","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/jac\/dkp503","article-title":"Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae","volume":"65","author":"Moisan","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.ijantimicag.2020.105921_bib0011","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/jac\/dkm150","article-title":"In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes","volume":"60","author":"Mushtaq","year":"2007","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.ijantimicag.2020.105921_bib0012","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1128\/AAC.49.8.3501-3512.2005","article-title":"Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains","volume":"49","author":"Sader","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.ijantimicag.2020.105921_bib0013","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ijantimicag.2020.105921_bib0014","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1164\/rccm.2102084","article-title":"Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria","volume":"166","author":"Angus","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2020.105921_bib0015","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s13054-016-1414-2","article-title":"Severe community-acquired pneumonia: timely management measures in the first 24 hours","volume":"20","author":"Phua","year":"2016","journal-title":"Crit Care"},{"issue":"2","key":"10.1016\/j.ijantimicag.2020.105921_bib0016","doi-asserted-by":"crossref","first-page":"R58","DOI":"10.1186\/cc13812","article-title":"Patients with community acquired pneumonia admitted to European intensive care units: an epidemiological survey of the GenOSept cohort","volume":"18","author":"Walden","year":"2014","journal-title":"Crit Care"},{"issue":"Suppl 2","key":"10.1016\/j.ijantimicag.2020.105921_bib0017","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/cc4927","article-title":"Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database","volume":"10","author":"Woodhead","year":"2006","journal-title":"Crit Care"},{"issue":"4","key":"10.1016\/j.ijantimicag.2020.105921_bib0018","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1179\/1973947814Y.0000000184","article-title":"Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience","volume":"26","author":"Ramani","year":"2014","journal-title":"J Chemother"},{"issue":"2","key":"10.1016\/j.ijantimicag.2020.105921_bib0019","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijantimicag.2019.05.023","article-title":"Clinical cure with ceftriaxone versus ceftaroline or ceftobiprole in the treatment of staphylococcal pneumonia: a systematic review and meta-analysis","volume":"54","author":"Eljaaly","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.ijantimicag.2020.105921_bib0020","article-title":"Efficacy and Safety of Ceftaroline for the Treatment of Community-Acquired Pneumonia: A Systemic Review and Meta-Analysis of Randomized Controlled Trials","volume":"8","author":"Lan","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.ijantimicag.2020.105921_bib0021","first-page":"1","article-title":"A look at clinical trial design for new antimicrobials for the adult population","author":"Bassetti","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2020.105921_bib0022","first-page":"iii19","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2020.105921_bib0023","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920300649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920300649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:37:09Z","timestamp":1760377029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920300649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0924857920300649"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105921","relation":{},"ISSN":["0924-8579"],"issn-type":[{"type":"print","value":"0924-8579"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105921"}}